NCT00186628: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Background	Acetaminophen	Small molecule	650 mg	Oral
Background	Cyclosporine	Peptide	6.25 mg/kg	Oral
Background	Diphenhydramine	Small molecule	50 mg	Intravenous
Background	Granisetron	Other / unclassified	1 mg	Oral
Background	Hydrocortisone	Other / unclassified	100 mg	Intravenous
Background	Methylprednisolone	Other / unclassified	1 mg/kg	—
Background	Mycophenolate Mofetil	Small molecule	15 mg/kg	Oral
Background	filgrastim	Protein / enzyme biologic	—	—
Background	rabbit anti-thymocyte globulin	Protein / enzyme biologic	1.5 mg/kg	—

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD